Anti-aging medicine has become a budding and rapidly growing
medical specialty as physicians who initially sought treatment for themselves have received training and
certification in its practice Clinical studies have shown that low-dose growth hormone (GH) treatment for adults with GH deficiency changes the body composition by increasing
muscle mass, decreasing fat mass, and increasing
bone density and muscle strength. It also improves
cardiovascular parameters (i.e. decrease of
LDL cholesterol) and affects the quality of life without significant side effects. However, it is also said to have potentially dangerous side effects when used in injectable form if proper protocols are not followed. It is not approved for use in healthy aging patients, though the restriction is occasionally sidestepped by means of a diagnosis of some injury, organic condition, or adult-growth-hormone deficiency which may have resulted in reduced secretion of the hormone.
Menopausal hormone drugs Administration of
estrogen and other hormones such as
progestin were popularized by the 1966 book
Feminine Forever by
Robert A. Wilson. However, the increase of the use of estrogen was shown to be associated with an increased risk of cancer. Later, in 2002, research into the long-term effects of estrogen on post-menopausal women, the
Women's Health Initiative, produced evidence that there were serious side effects. Physicians who prescribe the hormones now prescribe low doses of the drugs. Research into the long-term effects of hormone replacement therapy is continuing, with a 2025
Cochrane systematic review concluding that long-term use may decrease the risk of
bone fractures or
postmenopausal osteoporosis, but increase the risk of
stroke,
heart attacks,
endometrial cancer, and
breast cancer. Hormone therapy is generally only recommended for postmenopausal women who are at a high risk of osteoporosis when non-hormonal treatments are not suitable. Hormone therapy is not suitable or advised for treating cardiovascular disease, dementia, or for preventing cognitive decline in postmenopausal women. The risks of long-term hormonal therapy for women under 50 years of age have not been determined.
Senolytics ==Scientific approaches==